CA1005057A - Imidazolo-as-triazines - Google Patents

Imidazolo-as-triazines

Info

Publication number
CA1005057A
CA1005057A CA189,199A CA189199A CA1005057A CA 1005057 A CA1005057 A CA 1005057A CA 189199 A CA189199 A CA 189199A CA 1005057 A CA1005057 A CA 1005057A
Authority
CA
Canada
Prior art keywords
imidazolo
triazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA189,199A
Other languages
English (en)
Inventor
Robert W. Clarke
Alexander W. Oxford
David Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allen and Hanburys Ltd
Original Assignee
Allen and Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen and Hanburys Ltd filed Critical Allen and Hanburys Ltd
Application granted granted Critical
Publication of CA1005057A publication Critical patent/CA1005057A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA189,199A 1973-01-04 1973-12-28 Imidazolo-as-triazines Expired CA1005057A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB55373*[A GB1457873A (en) 1973-01-04 1973-01-04 Imidazotriazines

Publications (1)

Publication Number Publication Date
CA1005057A true CA1005057A (en) 1977-02-08

Family

ID=9706420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA189,199A Expired CA1005057A (en) 1973-01-04 1973-12-28 Imidazolo-as-triazines

Country Status (19)

Country Link
US (1) US3941785A (instruction)
JP (1) JPS4995994A (instruction)
AT (1) AT336029B (instruction)
AU (1) AU474078B2 (instruction)
BE (1) BE809369A (instruction)
CA (1) CA1005057A (instruction)
CH (1) CH618170A5 (instruction)
DE (1) DE2364076A1 (instruction)
ES (1) ES422001A1 (instruction)
FI (2) FI57260C (instruction)
FR (1) FR2213058B1 (instruction)
GB (1) GB1457873A (instruction)
IE (1) IE38681B1 (instruction)
IL (1) IL43872A (instruction)
LU (1) LU69099A1 (instruction)
NL (1) NL7400095A (instruction)
NO (1) NO140301C (instruction)
SE (1) SE408179B (instruction)
ZA (1) ZA739534B (instruction)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4096257A (en) * 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4107309A (en) * 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
US4126444A (en) * 1977-11-22 1978-11-21 American Cynamid Company Substituted imidazo (1,5-D)-as-triazin-4-ols, and herbicidal use thereof
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DD244681A3 (de) * 1985-12-02 1987-04-15 Zeiss Jena Veb Carl Vorrichtung zur positionierung von enden flexibler lichtleitelemente
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
DE19881732C1 (de) * 1997-11-12 2002-01-31 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
CZ293735B6 (cs) 1998-08-26 2004-07-14 Smithkline Beecham Corporation Farmaceutický prostředek pro léčbu plicní nemoci
ATE447952T1 (de) * 1999-08-21 2009-11-15 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
ES2278927T3 (es) * 2001-05-09 2007-08-16 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona.
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
ATE432936T1 (de) * 2003-04-01 2009-06-15 Smithkline Beecham Corp Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1931797A2 (en) * 2005-09-29 2008-06-18 Bayer HealthCare AG Pde inhibitors and combinations thereof for the treatment of urological disorders
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques

Also Published As

Publication number Publication date
ES422001A1 (es) 1976-08-01
NO140301B (no) 1979-04-30
JPS4995994A (instruction) 1974-09-11
IE38681B1 (en) 1978-05-10
US3941785A (en) 1976-03-02
FR2213058B1 (instruction) 1977-07-01
FI793137A7 (fi) 1981-01-01
DE2364076A1 (de) 1974-07-18
IL43872A0 (en) 1974-03-14
AT336029B (de) 1977-04-12
NO140301C (no) 1979-08-08
FR2213058A1 (instruction) 1974-08-02
IL43872A (en) 1979-01-31
SE408179B (sv) 1979-05-21
FI57260B (fi) 1980-03-31
ZA739534B (en) 1974-11-27
LU69099A1 (instruction) 1974-04-02
IE38681L (en) 1974-07-04
NL7400095A (instruction) 1974-07-08
AU474078B2 (en) 1976-07-15
FI57260C (fi) 1980-07-10
BE809369A (fr) 1974-07-03
GB1457873A (en) 1976-12-08
AU6377473A (en) 1975-06-19
CH618170A5 (instruction) 1980-07-15
ATA2374A (de) 1976-08-15

Similar Documents

Publication Publication Date Title
AU474137B2 (en) Auto-refractometer
AU468964B2 (en) Melik
CA1034948A (en) Triazolopyridazines
CA1031323A (en) D-homo-steroids
AU498889B2 (en) Piperidylene benzocycloheptathiophenes
CA1033713A (en) D-homo-steroids
CA1034957A (en) Fluoroaliphaticthiomethylsiloxanes
AU476397B2 (en) A-cycloalkylbenzyl lactamimides
AU476505B2 (en) Alkylbenxyl lactamimides
AU472907B2 (en) Firecheck
CA1034593A (en) Amidinoureas
CA998215A (en) Warmhouse
AU476386B2 (en) Dibenzocycloheptenyl lactamimides
CA1007225A (en) Polycycloanilines
AU471241B2 (en) Benzothiazolylureas
CA1019735A (en) Thienodiazepines
CA1022573A (en) M-fluroisopropylanilines
AU481998B2 (en) Benzenedisulfonamides
AU484993B2 (en) Polyhydroxyphenylchromanones
AU489560B2 (en) Amidinoureas
AU466103B2 (en) Cis-chrysanthemate
CA1023765A (en) Tertiary-alkylamino-lower acyl-xylidides
CA1012556A (en) Bis-2-amino-ethanols
AU486644B2 (en) Fusebox
AU478880B2 (en) 3-isoxazolidinones